Skip to content

Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients

Measuring Urinary Nano Particles and Arsenic and Comparing Them to Cystoscopic Findings and Urinary Cytology in Patients Suspected With Urinary Bladder Malignancy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02811952
Enrollment
100
Registered
2016-06-23
Start date
2016-06-23
Completion date
2021-01-01
Last updated
2022-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

bladder cancer

Brief summary

In many of urothelial carcinoma patients, one does not find common risk factors such as smoking. The medical center is located in an industrial city with known air and water pollution. The investigators decided to check the presence of nano particles and traces of metals in urinary samples of patients known and suspected for urothelial carcinoma and compare the results to both cystoscopic and cytological findings. The patients will fill a validated epidemiological respiratory disease survey and the results will be compared to a control group.

Interventions

without intervention

Sponsors

Carmel Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Study group : 1. Patients that need cystoscopy due to suspicion/known bladder malignancy. 2. Patients that can read, understand and sign an informed consent form. Control group: 1. Patients that need cystoscopy due to others reasons than malignancy. 2. Patients that present to the Department of Urology for surgery unrelated to malignancy of the urinary system ( prostatectomy, Incontinence repair, circumcision, hydrocele/ varicocele repair, ureteroscopy etc).

Exclusion criteria

Study group: 1. Patients receiving bladder irrigations, pregnant women, children and those with impaired judgment 2. Patients with a technically improper urine test. Control group 1. Patients receiving bladder irrigations, pregnant women, children and those with impaired judgment 2. Patients with a technically improper urine test.

Design outcomes

Primary

MeasureTime frame
levels of nano particles and arsenic in urineone year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026